OralDosed ingredientTherapeutic flag
Nifedipine
CAS 21829-25-4
Nifedipine (CAS 21829-25-4) is a Phase 4 pharmaceutical compound with 37 bioactivity targets and 3,642 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
52
SOURCE
DrugCentral
Adverse signals
3,642
SOURCE
IUPHAR/BPS
PubMed IDs
18
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Nifedipine
CAS Number
21829-25-4
UNII
I9ZF7L6G2L
InChIKey
HYIMSNHJOBLJNT-UHFFFAOYSA-N
ChEMBL ID
CHEMBL193
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Procardia
dosed ingredientnatural productoraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL193 | Small molecule
SOURCE
EMBL-EBI ChEMBL
52 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24892.10544217687 nM | 165 | - |
| - | IC50 | 11768.290170700637 nM | 154 | - |
| - | AC50 | 21079.51037313433 nM | 132 | - |
| - | Ki | 6041.9129 nM | 35 | - |
| - | EC50 | 2089.492227272727 nM | 22 | - |
| - | Kd | 3487.7177333333334 nM | 6 | - |
| Arachidonate 15-lipoxygenase Enzyme |
IC50 | 4.821 | - | Oryctolagus cuniculus |
| Adenosine receptor A1 GPCR |
Ki | 5.54 | - | Rattus norvegicus |
| Sodium/nucleoside cotransporter 1 Transporter |
Ki | 5.089 | - | Homo sapiens |
| Adenosine receptor A2a GPCR |
Ki | 4.65 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 4.3 | - | Homo sapiens |
| Cytochrome P450 3A4 Enzyme |
IC50 | 5.26 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 6.495 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 5.019 | - | Homo sapiens |
| Adenosine receptor A1 GPCR |
Ki | 5.348 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 5.08 | - | Homo sapiens |
| Glutathione reductase, mitochondrial Enzyme |
Ki | 4.76 | - | Homo sapiens |
| Transthyretin Secreted |
IC50 | 5.658 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 4.3 | - | Homo sapiens |
| Glycine receptor subunit alpha-1 Ion channel |
IC50 | 5.48 | - | Homo sapiens |
| Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel |
IC50 | 7.7 | - | Homo sapiens |
| Bile salt export pump Transporter |
IC50 | 4.51 | - | Homo sapiens |
| Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel |
Ki | 4.672 | - | Homo sapiens |
| Cytochrome P450 1A2 Enzyme |
IC50 | 6.523 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily A member 1 Ion channel |
IC50 | 4.02 | - | Homo sapiens |
| Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel |
IC50 | 6.3 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily A member 5 Ion channel |
IC50 | 5.21 | - | Homo sapiens |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme |
IC50 | 4.355 | - | Homo sapiens |
| Glycine receptor subunit beta Ion channel |
IC50 | 5.9 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily A member 2 Ion channel |
Kd | 4.7 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
IC50 | 5.69 | - | Homo sapiens |
| Thromboxane-A synthase Enzyme |
IC50 | 4.731 | - | Homo sapiens |
| C-C chemokine receptor type 2 GPCR |
Ki | 6.072 | - | Homo sapiens |
| Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel |
IC50 | 6 | - | Homo sapiens |
| Glycine receptor subunit alpha-3 Ion channel |
IC50 | 4.5 | - | Homo sapiens |
| Acetylcholinesterase Enzyme |
Ki | 5.4 | - | Electrophorus electricus |
| Adenosine receptor A2a GPCR |
Ki | 4.74 | - | Rattus norvegicus |
| Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel |
IC50 | 9 | - | Oryctolagus cuniculus |
| Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel |
Ki | 8.46 | - | Rattus norvegicus |
| Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel |
Ki | 8.92 | - | Rattus norvegicus |
| Cholinesterase Enzyme |
Ki | 5.92 | - | Equus caballus |
| Indoleamine 2,3-dioxygenase 2 Enzyme |
IC50 | 5.82 | - | Mus musculus |
| Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel |
IC50 | 8.59 | - | Cavia porcellus |
| Sodium channel alpha subunits; brain (Types I, II, III) Ion channel |
IC50 | 4.43 | - | Homo sapiens |
| Voltage-gated L-type calcium channel Ion channel |
Ki | 8.33 | - | Rattus norvegicus |
| Indoleamine 2,3-dioxygenase 1 Enzyme |
IC50 | 4.34 | - | Mus musculus |
| Bile salt export pump Transporter |
IC50 | 4.34 | - | Rattus norvegicus |
| Potassium voltage-gated channel subfamily A member 7 Ion channel |
IC50 | 4.9 | - | Mus musculus |
| Potassium voltage-gated channel subfamily A member 1 Ion channel |
IC50 | 4 | - | Mus musculus |
| Potassium voltage-gated channel subfamily A member 2 Ion channel |
Kd | 4.7 | - | Rattus norvegicus |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Premature baby | 683 | 935.717 | 10036590 |
| Premature delivery | 449 | 721.593 | 10036595 |
| Low birth weight baby | 296 | 463.908 | 10067508 |
| Foetal exposure during pregnancy | 592 | 419.547 | 10071404 |
| Exposure during pregnancy | 645 | 291.308 | 10073513 |
| Pre-eclampsia | 128 | 201.487 | 10036485 |
| Alopecia | 102 | 194.964 | 10001760 |
| Foetal growth restriction | 146 | 179.2 | 10070531 |
| Pemphigus | 22 | 166.858 | 10034280 |
| Renal impairment | 531 | 162.264 | 10062237 |
| Glossodynia | 27 | 149.754 | 10018388 |
| Hypotension | 1020 | 139.538 | 10021097 |
| Blood pressure inadequately controlled | 91 | 127.768 | 10051128 |
| Bradycardia | 417 | 122.424 | 10006093 |
| Cerebral infarction | 217 | 122.014 | 10008118 |
| Therapeutic product effect decreased | 68 | 117.713 | 10082201 |
| Systemic lupus erythematosus | 65 | 114.914 | 10042945 |
| Drug ineffective | 1212 | 113.44 | 10013709 |
| Cardiac failure congestive | 441 | 112.798 | 10007559 |
| Wound | 43 | 111.359 | 10052428 |
| Maternal exposure during pregnancy | 561 | 110.568 | 10071408 |
| Pericarditis | 24 | 109.647 | 10034484 |
| Blood creatinine increased | 457 | 105.678 | 10005483 |
| Shock | 195 | 105.479 | 10040560 |
| Aplastic anaemia | 120 | 103.738 | 10002967 |
| Proteinuria | 175 | 102.05 | 10037032 |
| Oedema peripheral | 652 | 101.983 | 10030124 |
| Contraindicated product administered | 97 | 101.399 | 10078504 |
| Duodenal ulcer perforation | 3 | 101.094 | 10013849 |
| Blood pressure increased | 603 | 98.343 | 10005750 |
| Caesarean section | 117 | 97.93 | 10006924 |
| Neovascularisation | 42 | 97.355 | 10029113 |
| Arthropathy | 110 | 97.139 | 10003285 |
| Hyperkalaemia | 339 | 96.79 | 10020646 |
| Discomfort | 56 | 96.681 | 10013082 |
| Hypersensitivity | 182 | 93.717 | 10020751 |
| Infusion related reaction | 155 | 91.481 | 10051792 |
| Treatment failure | 113 | 85.028 | 10066901 |
| Drug abuse | 45 | 84.437 | 10013654 |
| Drug interaction | 865 | 84.353 | 10013710 |
| Photodermatosis | 35 | 83.794 | 10051246 |
| Joint swelling | 221 | 83.466 | 10023232 |
| Premature labour | 87 | 82.991 | 10036600 |
| Folliculitis | 3 | 82.626 | 10016936 |
| Dysplastic naevus | 31 | 81.043 | 10062805 |
| Helicobacter infection | 13 | 80.959 | 10054263 |
| Blood urea increased | 190 | 80.418 | 10005851 |
| Neutropenia | 185 | 79.299 | 10029354 |
| Gingival hypertrophy | 51 | 78.957 | 10018284 |
| Rheumatoid factor positive | 9 | 76.052 | 10039080 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
15 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Ca v 1.1 Cacna1s |
Antagonist | 6.300000190734863 pIC50 | 2451745 |
| Ca v 1.2 Cacna1c |
Antagonist | 8.050000190734863 pIC50 | 11045961|7506331 |
| Ca v 1.3 CACNA1D |
Antagonist | 7.699999809265137 pIC50 | 19029287 |
| Ca v 1.4 CACNA1F |
Antagonist | 6.0 pIC50 | 14973233 |
| K v 1.1 Kcna1 |
Channel blocker | 4.0 pIC50 | 7517498 |
| K v 1.2 Kcna2 |
Pore blocker | 4.699999809265137 pKd | 7517498 |
| K v 1.5 KCNA5 |
Channel blocker | 4.1 pKd | 7517498 |
| K v 1.7 Kcna7 |
Channel blocker | 4.9 pIC50 | 9488722 |
| K v 3.1 Kcnc1 |
Channel blocker | 3.9 pIC50 | 7517498 |
| Pregnane X receptor NR1I2 |
Agonist | - | 9770465 |
| TRPM3 TRPM3 |
Activator | - | - |
| glycine receptor α1 subunit GLRA1 |
Antagonist | 5.5 pIC50 | - |
| glycine receptor α3 subunit GLRA3 |
Antagonist | 4.5 pIC50 | - |
| glycine receptor β subunit GLRB |
Antagonist | 5.900000095367432 pIC50 | - |
| glycine receptor β subunit GLRB |
Antagonist | 4.900000095367432 pIC50 | - |
SOURCE
PharmGKB
24 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
SLC14A2 (PA35811) rs1123617
Genotype AG is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.
Evidence: -; PMID 17344938
CYP3A (PA27114),"CYP3A4 (PA130)" rs4987161
Allele G is associated with decreased metabolism of nifedipine as compared to allele A.
Evidence: -; PMID 15634941
CYP3A (PA27114),"CYP3A4 (PA130)" rs4986913
Allele A is not associated with decreased metabolism of nifedipine as compared to allele G.
Evidence: -; PMID 15634941
ADRB2 (PA39) rs1042713
Genotypes AG + GG are not associated with increased response to nifedipine in people with Hypertension as compared to genotype AA.
Evidence: -; PMID 19444285
ADRB2 (PA39) rs1042714
Genotypes CG + GG are not associated with increased response to nifedipine in people with Hypertension as compared to genotype CC.
Evidence: -; PMID 19444285
ADRA1A (PA34) rs1048101
Genotypes AA + AG are associated with increased response to nifedipine in people with Hypertension as compared to genotype GG.
Evidence: -; PMID 19444285
ACE2 (PA425) rs2106809
Genotype GG is not associated with response to nifedipine in women with Hypertension as compared to genotypes AA + AG.
Evidence: -; PMID 17473847
CACNA1C (PA83) rs2239128
Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.
Evidence: -; PMID 16610939
CYP3A (PA27114),"CYP3A4 (PA130)" rs4986910
Allele G is not associated with decreased metabolism of nifedipine as compared to allele A.
Evidence: -; PMID 15634941
ACE (PA139) rs1799752
Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to nifedipine in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.
Evidence: -; PMID 15233837
MMP9 (PA30889) rs3918242
Genotype CT is associated with decreased response to Antihypertensives, hydralazine, Methyldopa or nifedipine in people with Gestational hypertension as compared to genotype CC.
Evidence: -; PMID 21769110
NOS1AP (PA142671259) rs10494366
Genotypes GG + GT are associated with increased risk of Death when treated with amlodipine, Dihydropyridine derivatives or nifedipine in people with Hypertension as compared to genotype TT.
Evidence: -; PMID 19076153
CYP3A4 (PA130) CYP3A4*1, CYP3A4*18
CYP3A4 *18 is not associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.
Evidence: -; PMID 15634941
SLC14A2 (PA35811) rs1123617
Genotype AA is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.
Evidence: -; PMID 17344938
SLC14A2 (PA35811) rs3745009
Genotype AA is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.
Evidence: -; PMID 17344938
CYP3A5 (PA131) rs776746
Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.
Evidence: -; PMID 22875663
CACNA1C (PA83) rs2238032
Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.
Evidence: -; PMID 16610939
CACNA1C (PA83) rs2239050
Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.
Evidence: -; PMID 16610939
SLC14A2 (PA35811) rs3745009
Genotype AG is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.
Evidence: -; PMID 17344938
SLC14A2 rs1123617
Hypertension
Evidence: 3; PMID 1
SLC14A2 rs3745009
Hypertension
Evidence: 3; PMID 1
CYP3A5 rs776746
Pregnancy
Evidence: 3; PMID 1
CYP3A4 CYP3A4*1, CYP3A4*17
-
Evidence: 3; PMID 1
ADRA1A rs1048101
Hypertension
Evidence: 3; PMID 1
SOURCE
NLM RxNorm
6 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Nifedipine | 7417 | SU | MTHSPL |
| nifedipine | 7417 | SU | MTHSPL |
| NIFEDIPINE | 7417 | SU | MTHSPL |
| nifedipine | 7417 | IN | RXNORM |
| NIFEdipine | 7417 | TMSY | RXNORM |
| Procardia | 203423 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | nifedipine | PT | C0232487 |
| Abdominal distension | nifedipine | PT | C0000731 |
| Abdominal pain | nifedipine | LLT | C0000737 |
| Abdominal pain | nifedipine | PT | C0000737 |
| Abnormal vision | nifedipine | LLT | C3665386 |
| Acute generalised exanthematous pustulosis | nifedipine | LLT | C0877055 |
| Acute generalised exanthematous pustulosis | nifedipine | PT | C0877055 |
| Acute pulmonary oedema | nifedipine | LLT | C0155919 |
| Acute pulmonary oedema | nifedipine | PT | C0155919 |
| Affect lability | nifedipine | PT | C0233472 |
| Agitation | nifedipine | PT | C0085631 |
| Agranulocytosis | nifedipine | LLT | C0001824 |
| Agranulocytosis | nifedipine | PT | C0001824 |
| Alanine aminotransferase increased | nifedipine | LLT | C0151905 |
| Alanine aminotransferase increased | nifedipine | PT | C0151905 |
| Allergic hepatitis | nifedipine | LLT | C1959797 |
| Allergic hepatitis | nifedipine | PT | C1959797 |
| Allergic oedema | nifedipine | LLT | C0847033 |
| Allergic oedema | nifedipine | PT | C0847033 |
| Alopecia | nifedipine | LLT | C0002170 |
| Alopecia | nifedipine | PT | C0002170 |
| Altered state of consciousness | nifedipine | PT | C0150450 |
| Amblyopia | nifedipine | LLT | C0002418 |
| Amblyopia | nifedipine | PT | C0002418 |
| Amnesia | nifedipine | LLT | C0002622 |
| Amnesia | nifedipine | PT | C0002622 |
| Anaemia | nifedipine | LLT | C0002871 |
| Anaemia | nifedipine | PT | C0002871 |
| Anaphylactic shock | nifedipine | LLT | C0002792 |
| Anaphylactic shock | nifedipine | PT | C0002792 |
| Anaphylactic shock | nifedipine | PT | C0002792 |
| Anaphylactoid reaction | nifedipine | LLT | C0340865 |
| Anaphylactoid reaction | nifedipine | PT | C0340865 |
| Angina pectoris | nifedipine | LLT | C0002962 |
| Angina pectoris | nifedipine | PT | C0002962 |
| Angina pectoris | nifedipine | PT | C0002962 |
| Angina pectoris aggravated | nifedipine | LLT | C0235467 |
| Angioedema | nifedipine | LLT | C0002994 |
| Angioedema | nifedipine | PT | C0002994 |
| Angiopathy | nifedipine | LLT | C0042373 |
| Angiopathy | nifedipine | PT | C0042373 |
| Anorexia | nifedipine | LLT | C0003123 |
| Anxiety | nifedipine | LLT | C0003467 |
| Anxiety | nifedipine | PT | C0003467 |
| Arrhythmia | nifedipine | LLT | C0003811 |
| Arrhythmia | nifedipine | PT | C0003811 |
| Arthralgia | nifedipine | LLT | C0003862 |
| Arthralgia | nifedipine | PT | C0003862 |
| Arthritis | nifedipine | LLT | C0003864 |
| Arthritis | nifedipine | PT | C0003864 |
| Arthropathy | nifedipine | LLT | C0022408 |
| Arthropathy | nifedipine | PT | C0022408 |
| Asthenia | nifedipine | LLT | C0004093 |
| Asthenia | nifedipine | PT | C0004093 |
| Asthenia | nifedipine | PT | C0004093 |
| Ataxia | nifedipine | LLT | C0004134 |
| Ataxia | nifedipine | PT | C0004134 |
| Atrial fibrillation | nifedipine | LLT | C0004238 |
| Atrial fibrillation | nifedipine | PT | C0004238 |
| Back pain | nifedipine | LLT | C0004604 |
| Back pain | nifedipine | PT | C0004604 |
| Bezoar | nifedipine | LLT | C1321581 |
| Bezoar | nifedipine | PT | C1321581 |
| Blindness transient | nifedipine | LLT | C0155003 |
| Blindness transient | nifedipine | PT | C0155003 |
| Blindness unilateral | nifedipine | PT | C0271240 |
| Blister | nifedipine | LLT | C0005758 |
| Blister | nifedipine | PT | C0005758 |
| Blood and lymphatic system disorders | nifedipine | - | C0851353 |
| Blood pressure increased | nifedipine | LLT | C0497247 |
| Blood pressure increased | nifedipine | PT | C0497247 |
| Body temperature increased | nifedipine | LLT | C0015967 |
| Body temperature increased | nifedipine | PT | C0015967 |
| Bradycardia | nifedipine | LLT | C0428977 |
| Bradycardia | nifedipine | PT | C0428977 |
| Breast disorder | nifedipine | LLT | C0006145 |
| Breast disorder | nifedipine | PT | C0006145 |
| Breast engorgement | nifedipine | LLT | C0085688 |
| Breast engorgement | nifedipine | PT | C0085688 |
| Breast pain | nifedipine | LLT | C0024902 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nifedipine used for in pharmaceutical contexts?
Nifedipine (CAS 21829-25-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nifedipine?
Nifedipine has 3,642 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Premature baby, Premature delivery, Low birth weight baby, Foetal exposure during pregnancy, Exposure during pregnancy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nifedipine also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Nifedipine.
What clinical phase is Nifedipine in?
Nifedipine is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Nifedipine?
Nifedipine has 52 bioactivity rows in this page query. Rendered target entries include Arachidonate 15-lipoxygenase, Adenosine receptor A1, Sodium/nucleoside cotransporter 1, Adenosine receptor A2a, Potassium voltage-gated channel subfamily H member 2.